Modelling and Simulation Group, School of Pharmacy Pharmacokinetic/Pharmacodynamic Understanding For Fentanyl IntraNasal in the Paediatric Population Aaron.

Slides:



Advertisements
Similar presentations
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Advertisements

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
PHT 415 BASIC PHARMACOKINETICS Course Instructor:Prf. Dr. Hnaa elsaghir Assistant lecturers, Doaa elshora and eman elfakih Text: Hand book of basic pharmacokinetics,
The higher BUP-to-NBUP ratio (0.7—19.19) than adults (0.165—1.4) has been observed in newborn patients studied. It might be due to immature hepatic function.
Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.
Principles of Pharmacology. SOURCES AND NAMES OF DRUGS Sources of Drugs Many drugs are isolated from plants or chemically derived from plant substances.
Pediatric Analgesic Use Debra L. Friedman MD Seattle Cancer Care Alliance.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
Michel J. Sabbagh, M.D., Maunak V. Rana, M.D. Intraoperative Intrasal Opioid Delivery Michel J. Sabbagh, M.D., Maunak V. Rana, M.D. Department of Anesthesiology,
Dose Adjustment in Renal and Hepatic Disease
Modelling and Simulation Group, School of Pharmacy Pharmacokinetic design optimization in children and estimation of maturation parameters: example of.
EMS Intranasal Medications: Prehospital Setting Todd Davis, MD, EMT-B Emergency Medicine University of Cincinnati Cincinnati, OH.
Clinical Pharmacy Part 2
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
© 2012 The McGraw-Hill Companies, Inc. All rights reserved. 1 Pharmacology: An Introduction CHAPTER.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
JOURNAL CLUB PRESENTATION First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric.
PK/PD Modeling in Support of Drug Development Alan Hartford, Ph.D. Associate Director Scientific Staff Clinical Pharmacology Statistics Merck Research.
You have learned a LOT so far. A few extra facts to throw in No single reproducible abnormality in any NT, enzyme, receptor or gene has been found to.
Orientation to Pharmacology
Animal Studies and Human Health Consequences Sorell L. Schwartz, Ph.D. Department of Pharmacology Georgetown University Medical Center.
U N I V E R S I T Y O F K E N T U C K Y - C O L L E G E O F P H A R M A C Y Pharmacokinetics & Drug Transport Philip E. Empey, Pharm.D., Ph.D., BCPS Assistant.
Mater Emergency Research in Children and Youth Pharmaco-governance of INF use in children in QLD Emergency Departments Amie Lloyd-Jones 4 th Year BPharm.
1 Axcan Public Presentation for the FDA Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting July 23, 2008.
Bioavailability Dr Mohammad Issa.
Modelling and Simulation Group, School of Pharmacy Intranasal Fentanyl in a Nutshell Aaron Basing.
FARMAKOKINETIKA. INTRODUCTION Historically, pharmaceutical scientists have evaluated the relative drug availability to the body in vivo after giving a.
Amie Lloyd-Jones QUM Project – Mater Children’s Emergency Department (Under supervision of Dr David Herd and Aaron Basing) University of Queensland.
Mater Emergency Research in Children and Youth Pharmaco-governance of INF use in children in QLD Emergency Departments Amie Lloyd-Jones 4 th Year BPharm.
PHARMACOKINETIC MODELS
Touqeer Ahmed Ph.D. Atta-ur-Rahman School of Applied Bioscience, National University of Sciences and Technology 21 st October, 2013.
A Randomised, Controlled Trial of Acetaminophen, Ibuprofen, and Codeine for Acute Pain relief in Children with Musculoskeletal Trauma Clark et al, Paediatrics.
Biopharmaceutics refers to the relationship of the:
Drug Administration Pharmacokinetic Phase (Time course of ADME processes) Absorption Distribution Pharmaceutical Phase Disintegration of the Dosage Form.
Chapter 35 Medication Administration. Scientific Knowledge Base To safely and accurately administer medications you need knowledge related to: ◦Pharmacology.
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Modelling and Simulation Group, School of Pharmacy Pharmacokinetic/Pharmacodynamic Understanding For Fentanyl IntraNasal in the Paediatric Population Aaron.
Pharmaceutics I صيدلانيات 1 Unit 2 Route of Drug Administration
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
INTRODUCTION CLINICAL PHARMACOKINETICS
BIOPHARMACEUTICS.
1 Pharmacokinetics: Introduction Dr Mohammad Issa.
Principles of pharmacokinetics Prof. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague Cycle II, Subject: General.
TDM Therapeutic Drug Monitoring
Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo.
Simultaneous evaluation of the activity of five cytochrome P450 enzymes by a cocktail study in healthy volunteers Department of Pharmacy Practice & Sciences.
European Patients’ Academy on Therapeutic Innovation The key principles of pharmacology.
Clinical Pharmacokinetic Equations and Calculations
Effect of Captopril first doses on Blood Pressure and Renal Function in Children with Congestive Cardiac Failure Dr Hussain Mulla, Co-Director, Centre.
PHT 415 BASIC PHARMACOKINETICS
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
1 CHAPTER 2 DEFINITIONS RELATED TO PHARMACOKINETICS.
Foundation Knowledge and Skills
DOSAGE ADJUSTMENT IN RENAL AND HEPATIC DISEASES Course Title : Biopharmaceutics and Pharmacokinetics – II Course Teacher : Zara Sheikh.
P AEDIATRICS EMC IV A DULT VERSUS CHILD Anatomy upper and lower airway anatomy. less compliant ventricles in the myocardium. larger skin surface.
INTRODUCTION TO PHARMACOKINETICS M. Kršiak Department of Pharmacology, Third Faculty of Medicine, Charles University in Prague, Charles University in Prague,
Methods The initial audit was carried out retrospectively, looking at the acute paediatric presentations from January 2014 to May 2014 inclusive. Patient.
Definitions and Concepts
Compartmental Models and Volume of Distribution
Pediatric Pharmacology Overview
Hanneke van der Lee, MD, PhD
Biopharmaceutics Dr Mohammad Issa Saleh.
Clinical Pharmacokinetics
Foundations and Principles of Pharmacology
Clinical Pharmacokinetics
Therapeutic Drug Monitoring chapter 1 part 1
Foundations and Principles of Pharmacology
Presentation transcript:

Modelling and Simulation Group, School of Pharmacy Pharmacokinetic/Pharmacodynamic Understanding For Fentanyl IntraNasal in the Paediatric Population Aaron Basing Supervisors Prof. Carl Kirkpatrick Dr David Herd A/Prof. Bruce Charles Dr Ross Norris PUFFIN

Modelling and Simulation Group, School of Pharmacy Overview Why study Intranasal Fentanyl (INF) in children Aims and Hypothesis Results so far

Modelling and Simulation Group, School of Pharmacy What is INF ? Fentanyl that is administered via the nasal route for analgesia

Modelling and Simulation Group, School of Pharmacy Fentanyl Micovic, I. V., M. D. Ivanovic, et al. (2000). "The synthesis and preliminary pharmacological evaluation of 4-methyl fentanyl." Bioorganic & medicinal chemistry letters 10(17):

Modelling and Simulation Group, School of Pharmacy Medical Uses of Fentanyl Multiple clinical applications –Anaesthesia Induction Maintenance –Analgesia Acute Chronic

Modelling and Simulation Group, School of Pharmacy Clinical Context Paediatric Emergency Room –Painful injuries are common  –Painful procedures are common Most frequent diagnoses of paediatric ED patients at PREDICT sites (n = presentations at nine sites) 2 Acworth, J., F. Babl, et al. (2009). "Patterns of presentation to the Australian and New Zealand Paediatric Emergency Research Network." Emergency medicine Australasia : EMA 21(1):

Modelling and Simulation Group, School of Pharmacy Clinical Context Pain in the emergency department is poorly treated –Oligoanalgesia –Delay in time to analgesia Todd, K. H., J. Ducharme, et al. (2007). "Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study." The journal of pain : official journal of the American Pain Society 8(6): N = 842

Modelling and Simulation Group, School of Pharmacy Why do we need INF ? Viable alternative to intravenous analgesia –Needleless –Rapid Absorption –Sterile technique not required

Modelling and Simulation Group, School of Pharmacy What we already know about INF It is effective IV morphine 0.1mg/kg INF 1.4 µg/kg Borland, M., I. Jacobs, et al. (2007). "A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department." Ann Emerg Med 49(3):

Modelling and Simulation Group, School of Pharmacy What we already know about INF It can reduce time to analgesia

Modelling and Simulation Group, School of Pharmacy Summary so far Painful injuries and procedures are common in paediatric emergency departments. INF has several features that are well suited to use within a paediatric emergency department

Modelling and Simulation Group, School of Pharmacy What we DON’T know about INF The underlying pharmacokinetics for INF in the paediatric population

Modelling and Simulation Group, School of Pharmacy What we don’t know about Dosing strategies have been developed empirically from adult pharmacokinetic studies  Potential for therapeutic catastrophe

Modelling and Simulation Group, School of Pharmacy Pharmacokinetics of Fentanyl ABSORPTION DISTRIBUTION METABOLISM EXCRETION

Modelling and Simulation Group, School of Pharmacy Pharmacokinetics in Adults ABSORPTION –Rapid, T max approx 10 minutes –Bioavailablity – 70-90% Drug Administration Drug in Blood Stream

Modelling and Simulation Group, School of Pharmacy What we know about the pharmacokinetics of fentanyl DISTRIBUTION –Octanol/Water Coefficient 9550 –Adipose Tissue – some –Skeletal muscle – some –Well Perfused organs – High Drug in Blood Stream Body Tissue

Modelling and Simulation Group, School of Pharmacy What we know about the pharmacokinetics of fentanyl METABOLISM Primarily N-Dealkylation to norfentanyl (inactive) by CYP3A4 Large variability in clearance –Genetic variability in CYP3A4 –Physiologic and pathophysiologic variability in liver blood flow Drug in Blood Stream Metabolites

Modelling and Simulation Group, School of Pharmacy What we know about the pharmacokinetics of fentanyl EXCRETION Kidney –10% Unchanged Faeces –1% Unchanged Drug in Blood Stream Drug outside of body

Modelling and Simulation Group, School of Pharmacy What we need to know INF Guestimate of pharmacokinetic parameters in paediatrics compared to adults –Clearance ? ↓ –Volume of Distribution ? ↓ –Nasal absorption rate constant ???? ↑↓

Modelling and Simulation Group, School of Pharmacy Why is this particularly important Fentanyl has serious side effects B. Yassen, A., J. Kan, et al. (2006). "Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory-depressant effect of buprenorphine and fentanyl in rats." J Pharmacol Exp Ther 319(2):

Modelling and Simulation Group, School of Pharmacy Why is this important Besides dosage other relevant clinical questions remain to be answered with science rather than anecdote –When should it start to work –When is it safe to re-dose

Modelling and Simulation Group, School of Pharmacy How we will determine the parameters of interest Population PK/PD modelling allows: –Optimal design data –Estimation of variability and affect of covariates –Allows “what if” experiments to be completed in silico

Modelling and Simulation Group, School of Pharmacy AIMS What we hope to achieve

Modelling and Simulation Group, School of Pharmacy AIM 1 Determine if varying techniques for the preparation and administration of intranasal fentanyl effect the amount of drug delivered

Modelling and Simulation Group, School of Pharmacy AIM 2 Using optimal design methodologies, design a trial protocol to study the population pharmacokinetics of intranasal fentanyl in paediatric patients

Modelling and Simulation Group, School of Pharmacy AIM Determine the most appropriate model to describe the relationship between administered dose of intranasal fentanyl and observed blood concentration in paediatric patients. Determine the most appropriate model to describe the relationship between blood concentration of fentanyl and pain score after administration of intranasal fentanyl to the paediatric population.

Modelling and Simulation Group, School of Pharmacy AIM 5 Perform simulations to answer clinically relevant questions for the treatment of acute or procedural pain in paediatric patients by INF

Modelling and Simulation Group, School of Pharmacy Results so far For statistical optimisation of a trial design we must have some idea of the underlying model –Problem!!! No studies report the pharmacokinetics of INF in children

Modelling and Simulation Group, School of Pharmacy Results so far However we do have Adult INF studies Expolate using a linear relationship between weight and dose

Modelling and Simulation Group, School of Pharmacy How do we use adult data This is not a linear relationship Gillooly, J. F., J. H. Brown, et al. (2001). "Effects of size and temperature on metabolic rate." Science 293(5538):

Modelling and Simulation Group, School of Pharmacy How do we use adult data Allometric Scaling

Modelling and Simulation Group, School of Pharmacy Allometry doesn’t explain it all Anderson, B. J. and N. H. Holford (2009). "Mechanistic basis of using body size and maturation to predict clearance in humans." Drug Metab Pharmacokinet 24(1):

Modelling and Simulation Group, School of Pharmacy How do we use adult data Maturation Function Sumpter, A. and B. J. Anderson (2009). "Pediatric pharmacology in the first year of life." Curr Opin Anaesthesiol 22(4):

Modelling and Simulation Group, School of Pharmacy Putting it all together

Modelling and Simulation Group, School of Pharmacy Sampling times and windows Run competing maturation models and varying allometric exponents for varying age.  Database of different sampling times for different ages  Do the sampling windows overlap???

Modelling and Simulation Group, School of Pharmacy Other significant milestones Review paper of Transmucosal opiates in paediatrics in progress Competency in Assay Technique LC MS/MS

Modelling and Simulation Group, School of Pharmacy What still needs to do be done

Modelling and Simulation Group, School of Pharmacy Acknowledgements Supervisors ACPP Laboratory staff Mater Children’s Emergency Department QUM and Medical Students QEMRF Modelling and simulation group members

Modelling and Simulation Group, School of Pharmacy QUESTIONS ?

Modelling and Simulation Group, School of Pharmacy